Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA has spent the past five years moving from a structurally challenged, conglomerate-like healthcare group toward a more focused, deleveraging operation. By early 2026, what was once seen as a troubled turnaround is now perceived as a successfully executing recovery story with improving fundamentals and a substantially higher share price. The latest phase (2024–2025) is characterized by solid organic growth at Kabi and Helios, decisive portfolio simplification through the exit from Vamed subsegments, improved ratings outlooks, and upgraded guidance—all of which have driven the strong rerating to the current price level.

2021 to early 2022: Pre-turnaround strain

Fresenius operated with a complex portfolio including Fresenius Kabi, Helios, and Vamed's project and rehab operations, which exposed the group to construction risk and volatile cash flows. Margin pressure in Kabi's IV generics and COVID-related burdens in hospitals kept earnings modest while leverage climbed toward the mid-4x area by 2023 estimates. The investor narrative shifted toward skepticism—Fresenius looked like a value trap, with structurally pressured pharma economics, regulatory risk in German hospitals, and a balance sheet strained relative to growth prospects.

Mid-2022 to 2023: Strategic reset and FutureFresenius

Management initiated the #FutureFresenius transformation, refocusing on two core pillars—Kabi and Helios—and planning to simplify or exit non-core, structurally weaker parts, particularly Vamed's project and rehab units. Cost-saving programs accelerated; by Q1 2024 the group had already achieved €305m of cumulative structural savings against a €400m target for 2025, signaling tangible self-help. The regulatory and macro backdrop remained difficult, yet Fresenius held EBITDA margins broadly stable around 15% in 2022–2023. The investor narrative shifted from "structural value trap" toward "complex turnaround"—investors watched whether management could deliver disposals, cost savings, and deleveraging without sacrificing hospital or pharma competitiveness.

2024: Portfolio simplification and rating outlook upgrade

Fresenius announced plans to divest two major Vamed subsegments: approximately 67% of its rehab business (40% of Vamed sales) and all Austrian project business (15%), along with a phased shutdown of most remaining Health Tech Engineering project activities by 2026, leaving only high-end hospital services. S&P revised the outlook to stable from negative in June 2024, explicitly citing clear operational recovery, a leaner structure, and improved deleveraging prospects. The agency projected adjusted EBITDA margins at almost 16% in 2024 and 16.4–16.8% in 2025, with free cash flow of €1.3–1.6bn and adjusted leverage falling to about 3.5x in 2024 and close to 3.0x in 2025—a marked improvement from an estimated 4.2x in 2023. Kabi's growth vectors (biopharma, med-tech, nutrition) and Helios' stable hospital cash generation were highlighted as key drivers. The investor narrative increasingly became "deleveraging turnaround," with the story pivoting to execution of disposals, growth in high-value Kabi segments, and sustained hospital margins, with rating-agency confirmation acting as a major sentiment tailwind.

2025: Execution phase—growth, margins, deleveraging

FY 2025 results showed group revenue at €22.55bn, up 7% organically versus 2024, with EBIT growing 6% at constant currency to €2.60bn and an EBIT margin of 11.5% before special items. Core EPS rose 12% in constant currency to €2.87, reflecting operating leverage and significantly lower interest expense, while net income before special items reached €1.62bn. Net debt to EBITDA improved to 2.7x, inside a tightened self-imposed target corridor of 2.5–3.0x, evidencing substantial progress from higher leverage levels a few years earlier. Fresenius raised its structural EBIT-margin ambition for Kabi to 17–19% (from 16–18%), underlining confidence in the profitability of biopharma, med-tech and nutrition as the portfolio mix shifts away from low-margin IV generics. Biosimilars emerged as a central growth engine, with Kabi's biosimilars revenue growing 117% year-on-year in Q1 2024 and expected to rise 70–80% in 2024 and 40–50% in 2025, with biopharma forecast to reach at least 11% of Kabi revenue by 2025. Strategic moves included majority acquisition-driven scaling of biosimilars via mAbxience, a licensing agreement with Polpharma Biologics for a vedolizumab biosimilar, and the launch of denosumab biosimilars Conexxence and Bomyntra in Europe. By late 2025, the stock was increasingly seen as a "self-help healthcare compounder"—not a high-growth story, but a solid, de-risked platform with improving mix, visible cash generation and disciplined capital allocation, trading up from distressed valuations perceived in earlier years.

Early 2026: Rejuvenated equity story and technical backdrop

By February 2026, Fresenius characterized 2025 as a pivotal year where #FutureFresenius "REJUVENATE" delivered accelerated performance, upgraded guidance, and further balance-sheet strengthening. New guidance for 2026 targets 4–7% organic revenue growth and 5–10% Core EPS growth at constant currency. The company proposed a dividend of €1.05 per share for FY 2025, up 5%, within a 30–40% payout range, reinforcing the message of sustainable cash generation and restored financial flexibility. Additional strategic steps in late 2025 and early 2026—including AI-driven biomanufacturing collaborations via mAbxience, partnerships in cell and gene therapy manufacturing, U.S. epinephrine supply-chain localization with Phlow, and continued disposals in non-core homecare operations—strengthened the image of Fresenius as a more focused, innovation-aligned healthcare group. The investor narrative as of early 2026 centered on a "credibly executed turnaround" with an emerging compounder angle, centered on Kabi's higher-value platforms and Helios' hospital scale, underpinned by an investment-grade-comfortable leverage profile and a more straightforward equity story.

Approximate five-year technical phases

From 2021 into 2022, a persistent downtrend played out with lower highs and lower lows as earnings quality concerns, hospital regulatory risk, and leverage worries weighed on the multiple; the stock traded like a pressured value story within German healthcare. Through 2022–2023, a broad, volatile bottoming range formed as #FutureFresenius and cost-saving measures were introduced; rallies on restructuring headlines and disposal signals repeatedly faded on macro and execution doubts, but downside progressively became more contained. During 2024, the first durable uptrend leg arrived as Vamed divestment plans, visible structural savings, and the S&P outlook revision to stable drove a rerating, with breakouts above prior multi-year resistance levels supported by improving earnings quality and forward guidance. From 2025 into early 2026, a sustained advance unfolded with higher highs, reflecting strong 2025 results (7% organic growth, 12% Core EPS growth), leverage falling to the 2.7x area, and the market increasingly pricing in a structurally higher margin and growth profile for Kabi and Helios. Over the full five years, the share delivered around 20% total price performance, with the main value creation compressed into the post-turnaround rally of the last 2–3 years following the deep derating earlier in the period.